Abstract
The purpose of this study was to determine the mechanisms responsible for intestinal disposition of apigenin in the human Caco-2 cell culture model. The results indicated that most of the absorbed apigenin (10 μM) were conjugated and only a small fraction was transported intact. The amounts of conjugates excreted, especially that of the sulfate, were dependent on days-post-seeding. Apical efflux of apigenin sulfate did not change with concentration of apigenin (4 to 40 μM), whereas its basolateral efflux increased (p < 0.01) with concentration and plateaued at about 25 μM. In contrast, sulfate formation rates in cell lysate increased with concentration and plateaued at 25 μM and were 4 to 6 times faster than the corresponding excretion rates. Formation and polarized excretion rates of glucuronidated apigenin increased with apigenin concentration but formation rates were usually 2.5 to 6 times faster than the corresponding excretion rates. Inhibitors of multidrug resistance-related proteins (MRPs) such as leukotriene C4 and MK-571, which inhibited glucuronidation of apigenin at a high concentration (≥25 μM), significantly decreased excretion of both apigenin conjugates, and higher concentrations of MK-571 increased the extent of inhibition. In contrast, an organic anion transporter (OAT) inhibitor estrone sulfate only inhibited excretion of apigenin sulfate. In conclusion, we have shown for the first time that intestinal efflux is the rate-limiting step in the intestinal excretion of phase II conjugates of flavones. Furthermore, MRP and OAT are involved in the intestinal efflux of these hydrophilic phase II conjugates.
Footnotes
-
DOI: 10.1124/jpet.103.053496.
-
This work was supported by National Institutes of Health Grants AT00182 and CA87779.
-
ABBREVIATIONS: HBSS, Hanks' balanced salt solution; HPLC, high pressure liquid chromatography; MRP, multidrug resistance-related protein; OAT, organic anion transporter; UGT, UDP-glucuronosyltransferase.
- Received April 24, 2003.
- Accepted June 10, 2003.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|